-
公开(公告)号：US11912748B2
公开(公告)日：2024-02-27
申请号：US17314629
申请日：2021-05-07
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea Mahr , Toni Weinschenk , Helen Hoerzer , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC: C07K14/47 , C07K14/74 , A61K39/00 , C12N15/115 , C07K7/08 , C07K7/06 , C07K16/28 , C12N5/0783 , A61K35/17 , C07K16/30 , C12P21/02 , C12Q1/6881 , G01N33/569 , C07K14/82 , C07K16/32 , C12Q1/6886 , G01N33/574 , C07K14/705 , C07K16/18 , A61K38/00 , A61K35/12
CPC classification number: C07K14/4748 , A61K35/17 , A61K39/0011 , C07K7/06 , C07K7/08 , C07K14/4705 , C07K14/4738 , C07K14/705 , C07K14/70539 , C07K14/82 , C07K16/18 , C07K16/28 , C07K16/2833 , C07K16/30 , C07K16/303 , C07K16/3015 , C07K16/3023 , C07K16/3038 , C07K16/3046 , C07K16/3053 , C07K16/3069 , C07K16/32 , C12N5/0636 , C12N15/115 , C12P21/02 , C12Q1/6881 , C12Q1/6886 , G01N33/56977 , G01N33/57449 , G01N33/57492 , A61K38/00 , A61K39/00 , A61K2035/124 , A61K2039/5158 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N2310/16 , C12N2320/30 , C12N2501/50 , C12N2501/998 , C12Q2600/158 , G01N2333/70539
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US11485765B2
公开(公告)日：2022-11-01
申请号：US16713157
申请日：2019-12-13
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea Mahr , Toni Weinschenk , Helen Hoerzer , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC: A61K39/00 , C07K14/47 , C07K14/74 , C12N15/115 , C07K7/08 , C07K7/06 , C07K16/28 , C12N5/0783 , A61K35/17 , C07K16/30 , C12P21/02 , C12Q1/6881 , G01N33/569 , C07K14/82 , C07K16/32 , C12Q1/6886 , G01N33/574 , C07K14/705 , C07K16/18 , A61K38/00 , A61K35/12
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US11384129B2
公开(公告)日：2022-07-12
申请号：US17530443
申请日：2021-11-18
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Andrea Mahr , Toni Weinschenk , Helen Hoerzer , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC: A61K39/00 , C07K14/47 , C07K14/74 , C12N15/115 , C07K7/08 , C07K7/06 , C07K16/28 , C12N5/0783 , A61K35/17 , C07K16/30 , C12P21/02 , C12Q1/6881 , G01N33/569 , C07K14/82 , C07K16/32 , C12Q1/6886 , G01N33/574 , C07K14/705 , C07K16/18 , A61K38/00 , A61K35/12
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US10253076B2
公开(公告)日：2019-04-09
申请号：US15199066
申请日：2016-06-30
Applicant: immatics biotechnologies GmbH
Inventor： Andrea Mahr , Toni Weinschenk , Helen Hoerzer , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC: C07K14/47 , C07K14/74 , A61K39/00 , C12N15/115 , C07K7/08 , C07K7/06 , C07K16/28 , C12N5/0783 , A61K35/17 , C07K16/30 , C12P21/02 , C12Q1/6881 , G01N33/569 , C07K14/82 , C07K16/32 , C12Q1/6886 , G01N33/574 , C07K14/705 , C07K16/18 , A61K38/00 , A61K35/12
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
5.发明申请公开(公告)号：US20180346538A1
公开(公告)日：2018-12-06
申请号：US16101081
申请日：2018-08-10
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Andrea Mahr , Toni Weinschenk , Helen Hoerzer , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC: C07K14/47 , G01N33/574 , A61K39/00 , C07K7/06 , C07K7/08 , C07K14/705 , C07K14/74 , C07K14/82 , C07K16/18 , C07K16/28 , C07K16/30 , A61K35/17 , G01N33/569 , C12Q1/6886 , C12Q1/6881 , C12P21/02 , C12N15/115 , C12N5/0783 , C07K16/32 , A61K38/00 , A61K35/12
CPC classification number: C07K14/4748 , A61K35/17 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2035/124 , A61K2039/5158 , C07K7/06 , C07K7/08 , C07K14/4705 , C07K14/4738 , C07K14/705 , C07K14/70539 , C07K14/82 , C07K16/18 , C07K16/28 , C07K16/2833 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3046 , C07K16/3053 , C07K16/3069 , C07K16/32 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N5/0636 , C12N15/115 , C12N2310/16 , C12N2320/30 , C12N2501/50 , C12N2501/998 , C12P21/02 , C12Q1/6881 , C12Q1/6886 , C12Q2600/158 , G01N33/56977 , G01N33/57449 , G01N33/57492 , G01N2333/70539
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
Patent Agency Ranking
公开(公告)号：US09908922B2
公开(公告)日：2018-03-06
申请号：US15199199
申请日：2016-06-30
Applicant: immatics biotechnologies GmbH
Inventor： Andrea Mahr , Toni Weinschenk , Helen Hoerzer , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC: A01N61/00 , A61K31/00 , C07K14/47 , C07K14/74 , A61K39/00 , C12N15/115 , C07K7/08 , C07K7/06 , C07K16/28 , C12N5/0783 , A61K35/17 , C07K16/30 , C12P21/02 , C12Q1/68 , G01N33/569 , C07K14/82 , C07K16/32 , G01N33/574 , C07K14/705 , C07K16/18 , A61K38/00 , A61K35/12
CPC classification number: C07K14/4748 , A61K35/17 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2035/124 , A61K2039/5158 , C07K7/06 , C07K7/08 , C07K14/4705 , C07K14/4738 , C07K14/705 , C07K14/70539 , C07K14/82 , C07K16/18 , C07K16/28 , C07K16/2833 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3046 , C07K16/3053 , C07K16/3069 , C07K16/32 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N5/0636 , C12N15/115 , C12N2310/16 , C12N2320/30 , C12N2501/50 , C12N2501/998 , C12P21/02 , C12Q1/6881 , C12Q1/6886 , C12Q2600/158 , G01N33/56977 , G01N33/57449 , G01N33/57492 , G01N2333/70539
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US12071458B2
公开(公告)日：2024-08-27
申请号：US17530456
申请日：2021-11-18
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Andrea Mahr , Toni Weinschenk , Helen Hoerzer , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC: A61K39/00 , A61K35/17 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/705 , C07K14/74 , C07K14/82 , C07K16/18 , C07K16/28 , C07K16/30 , C07K16/32 , C12N5/0783 , C12N15/115 , C12P21/02 , C12Q1/6881 , C12Q1/6886 , G01N33/569 , G01N33/574 , A61K35/12 , A61K38/00
CPC classification number: C07K14/4748 , A61K35/17 , A61K39/0011 , C07K7/06 , C07K7/08 , C07K14/4705 , C07K14/4738 , C07K14/705 , C07K14/70539 , C07K14/82 , C07K16/18 , C07K16/28 , C07K16/2833 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3046 , C07K16/3053 , C07K16/3069 , C07K16/32 , C12N5/0636 , C12N15/115 , C12P21/02 , C12Q1/6881 , C12Q1/6886 , G01N33/56977 , G01N33/57449 , G01N33/57492 , A61K2035/124 , A61K38/00 , A61K39/00 , A61K2039/5158 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N2310/16 , C12N2320/30 , C12N2501/50 , C12N2501/998 , C12Q2600/158 , G01N2333/70539
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US11912749B2
公开(公告)日：2024-02-27
申请号：US17519637
申请日：2021-11-05
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea Mahr , Toni Weinschenk , Helen Hoerzer , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC: C07K14/47 , A61K35/17 , A61K39/00 , C07K7/06 , C07K7/08 , C07K14/705 , C07K14/74 , C07K14/82 , C07K16/18 , C07K16/28 , C07K16/30 , C07K16/32 , C12N5/0783 , C12N15/115 , C12P21/02 , C12Q1/6881 , C12Q1/6886 , G01N33/569 , G01N33/574 , A61K38/00 , A61K35/12
CPC classification number: C07K14/4748 , A61K35/17 , A61K39/0011 , C07K7/06 , C07K7/08 , C07K14/4705 , C07K14/4738 , C07K14/705 , C07K14/70539 , C07K14/82 , C07K16/18 , C07K16/28 , C07K16/2833 , C07K16/30 , C07K16/303 , C07K16/3015 , C07K16/3023 , C07K16/3038 , C07K16/3046 , C07K16/3053 , C07K16/3069 , C07K16/32 , C12N5/0636 , C12N15/115 , C12P21/02 , C12Q1/6881 , C12Q1/6886 , G01N33/56977 , G01N33/57449 , G01N33/57492 , A61K38/00 , A61K39/00 , A61K2035/124 , A61K2039/5158 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N2310/16 , C12N2320/30 , C12N2501/50 , C12N2501/998 , C12Q2600/158 , G01N2333/70539
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US11384127B2
公开(公告)日：2022-07-12
申请号：US17514822
申请日：2021-10-29
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea Mahr , Toni Weinschenk , Helen Hoerzer , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC: A61K39/00 , C07K14/47 , C12N15/115 , C07K7/08 , C07K7/06 , C07K16/28 , C12N5/0783 , A61K35/17 , C07K16/30 , C12P21/02 , C12Q1/6881 , G01N33/569 , C07K14/82 , C07K16/32 , C12Q1/6886 , G01N33/574 , C07K14/705 , C07K16/18 , C07K14/74 , A61K38/00 , A61K35/12
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
10.发明授权公开(公告)号：US10675338B1
公开(公告)日：2020-06-09
申请号：US16752156
申请日：2020-01-24
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea Mahr , Toni Weinschenk , Helen Hoerzer , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC: A61K35/17 , A61K39/00 , C07K14/72 , C07K16/00 , C07K16/28 , A61K38/08 , A61P35/02 , C12N15/115 , C07K14/725 , C07K14/47 , C07K7/06 , A61K38/17 , A61P35/00 , A61K39/39 , A61K38/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
-
Search Results
40
records
(took 0.073 seconds)
